Navigation Links
PhRMA CEO John Castellani Responds to Mid-Term Election, Stresses Importance of Innovation to Help Grow Economy
Date:11/3/2010

WASHINGTON, Nov. 3, 2010 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani released the following statement and video regarding the mid-term election:

Watch the Video

"Congratulations to all of the candidates who worked so hard on the campaign trail to earn the trust and votes of the American public.

"Two issues dominated the election this year: the state of our economy and jobs.

"There is no doubt that the last several years have been very tough for America and its workers.

"This is why it's so important for our nation's leaders to recognize the important role that America's biopharmaceutical research companies play in contributing to the national economy and creating millions of U.S. jobs as they develop medical advances.

"One way we can help our economy grow is to ensure that America remains the worldwide hub for scientific and medical research.

"When it comes to medical innovation, our nation is at a crossroads and it's up to our leaders to decide what path they want to take. Do they want to support the innovative engines that fuel America's economy, or do they want to let other countries win the race for knowledge, jobs and growth in the life sciences field?

"We believe the right path is one that strengthens the scientific and economic environments that foster medical advancements and serve as the foundations for great jobs and U.S. global competitiveness.

"Over the last couple of months, people have asked me why I took the job to lead PhRMA. My response is simple: I want to represent the most research-intensive sector in the U.S. Our companies are dedicated to improving and saving the lives of millions of patients worldwide and their work is also vital to our nation's economic prospects.

"I've had the honor of meeting many of the men and women working at biopharmaceutical companies who are researching and developing new medicines that can help patients battle diseases such as cancer, HIV/AIDS, heart disease and Alzheimer's. Collectively and individually, their passion, their ingenuity, their vision and, perhaps most importantly their determination, are resources that can't be taken for granted. They must be preserved and cultivated to reach even greater heights.

"Rest assured, America's biopharmaceutical companies are striving to achieve the next breakthrough. For example, consider Alzheimer's – PhRMA just released a report showing that our companies are working on nearly 100 new medicines for patients battling this devastating disease and related dementias.

"I urge you to check out the personal stories of company researchers, some of whom have inspirational stories about loved ones suffering from Alzheimer's, who are working on future treatments that could hold the key to eliminating the pain caused by this disease and helping to control related health care costs.

"The Alzheimer's Association recently estimated that the development of a new treatment that delays the onset of Alzheimer's could reduce Medicare and Medicaid spending on patients with the disease by more than $100 billion annually by 2030.

"In today's economic climate, we can't afford to ignore these potential savings.

"Congratulations again to our elected officials. We look forward to working with the new Congress on all of these important issues in the months and years ahead."

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $45.8 billion in 2009 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.3 billion in 2009.

PhRMA Internet Address: http://www.phrma.org

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For more information on public health emergencies, visit: http://www.rxresponse.org

For information on the danger of imported drugs, visit: http://www.buysafedrugs.info


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PhRMA Statement on Senate Finance Committee Vote
2. PhRMA Statement Supporting Fair Incentives for Biologics Innovation
3. Seven New Biopharmaceutical Research Companies Join PhRMAs Mission to Advance Medical Innovation
4. PhRMA Honors Patient Advocates Ron and Raychel Bartek
5. Pfizers Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts
6. PhRMA Statement on Health Care Reform
7. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
8. Roche responds to announcement of IDEAL hepatitis C trial results
9. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
10. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
11. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SAN JOSE, Calif. , Feb. 12, 2016  SI-BONE, Inc., ... Implant System ® ("iFuse"), a minimally invasive surgical (MIS) device ... announced that National Government Services, Inc. (NGS), the Medicare Administrative Contractor ... Illinois , Maine , ... Hampshire , New York , ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
Breaking Medicine Technology:
(Date:2/12/2016)... GA (PRWEB) , ... February 12, 2016 , ... ... relationship-marketing firm announced that nominations have closed for the ISE Southeast Awards 2016. ... will be announced at the ISE® Southeast Executive Forum and Awards Gala on ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO ... Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern ... Nevada Healthcare System. This will be the first Fisher House in Nevada, and ...
(Date:2/12/2016)... ... ... Erlanger Agency has announced a new partnership in its ongoing community involvement ... the fight against breast cancer, fundraising for a local woman named Carmen, who is ... is a loving single mother of two boys who also serves as caregiver for ...
(Date:2/12/2016)... Lakeland, FL (PRWEB) , ... February 12, 2016 , ... ... Coast Dental hygienist Suzan Sweeney, RDH, and dental assistant Terrell Moore shortly before 7 ... They joined dozens of dental professionals, donating their time and skills to help hundreds ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Drug Categories: Strategies for Health Plans and PBMs,” an upcoming Feb. 24 webinar ... affordability and access in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C ...
Breaking Medicine News(10 mins):